Abstract
Inositol phospholipid signaling pathways have begun to emerge as important players in stem cell biology and bone marrow transplantation [1-4]. The SH2-containing Inositol Phosphatase (SHIP) is among the enzymes that can modify endogenous mammalian phosphoinositides. SHIP encodes an isoform specific to pluripotent stem (PS) cells [5,6] plays a role in hematopoietic stem (HS) cell biology [7,8] and allogeneic bone marrow (BM) transplantation [1,2,9,10]. Here I discuss our current understanding of the cell and molecular pathways that SHIP regulates that influence PS/HS cell biology and BM transplantation. Genetic models of SHIP-deficiency indicate this enzyme is a potential molecular target to enhance both autologous and allogeneic BM transplantation. Thus, strategies to reversibly target SHIP expression and their potential application to stem cell therapies and allogeneic BMT are also discussed.
Keywords: phosphorylation, microenvironment, antigen presenting cells, Natural Killer cells, transplantation
Current Stem Cell Research & Therapy
Title: A Role for SHIP in Stem Cell Biology and Transplantation
Volume: 3 Issue: 2
Author(s): William G. Kerr
Affiliation:
Keywords: phosphorylation, microenvironment, antigen presenting cells, Natural Killer cells, transplantation
Abstract: Inositol phospholipid signaling pathways have begun to emerge as important players in stem cell biology and bone marrow transplantation [1-4]. The SH2-containing Inositol Phosphatase (SHIP) is among the enzymes that can modify endogenous mammalian phosphoinositides. SHIP encodes an isoform specific to pluripotent stem (PS) cells [5,6] plays a role in hematopoietic stem (HS) cell biology [7,8] and allogeneic bone marrow (BM) transplantation [1,2,9,10]. Here I discuss our current understanding of the cell and molecular pathways that SHIP regulates that influence PS/HS cell biology and BM transplantation. Genetic models of SHIP-deficiency indicate this enzyme is a potential molecular target to enhance both autologous and allogeneic BM transplantation. Thus, strategies to reversibly target SHIP expression and their potential application to stem cell therapies and allogeneic BMT are also discussed.
Export Options
About this article
Cite this article as:
Kerr G. William, A Role for SHIP in Stem Cell Biology and Transplantation, Current Stem Cell Research & Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157488808784223050
DOI https://dx.doi.org/10.2174/157488808784223050 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Stem Cells, Cancer, Liver, and Liver Cancer Stem Cells: Finding a Way Out of the Labyrinth...
Current Cancer Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Determination of 7,12-Dimethylbenz[a]Anthracene in Orally Treated Rats by High-Performance Liquid Chromatography and Transfer Stripping Voltammetry
Combinatorial Chemistry & High Throughput Screening New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Apoptosis in Drug Response
Current Pharmacogenomics Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews